With the annual ADA Scientific sessions this past week, there were many announcements and press releases from companies. I’ll be sharing a few that stood out to me…
Xeris Pharmaceuticals, Inc. Announces Dosing of First Patient in Phase 2 Clinical Trial of its Investigational Soluble Glucagon for the Treatment of Mild-to-Moderate Hypoglycemia
“Xeris’ G-Pen MiniTM (glucagon injection), a room-temperature stable glucagon product, is intended to be an effective and convenient treatment for mild-to-moderate hypoglycemia or low blood sugar. Currently, glucagon is only approved for use in the glucagon emergency kits (GEKs) marketed by Eli Lilly and Company and Novo Nordisk for the treatment of severe hypoglycemia. However, with these products, glucagon is available only as a dry powder in a sealed vial that must be reconstituted using a water-filled syringe in a multi-step process prior to injection. Xeris’ glucagon formulation is a stable, ready-to-inject liquid that can be packaged and delivered with a variety of devices including auto- injectors, pumps, and multi-dose pens (the latter in the form of the G-Pen MiniTM (glucagon injection) being the focus of this study).”
My take: Ready to inject glucagon is big on so many levels. First, people really freak out when you demonstrate how to use glucagon. Way too many steps that they don’t think they will remember…not to mention the huge needle. Even we, as d-parents, find it a little daunting to do in an emergency. Second, mini glucagon can be very useful during illness when stubborn low blood sugars just won’t come up, but the child is vomiting and can’t keep down food. Third, stable glucagon will likely be an important component of the artificial pancreas.